# US 7,608,690 B2 · IL-B30 antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,608,690 B2
- Document ID: US7608690B2
- Status: Granted
- Kind: B2
- Application number: 11/006,154
- Filed: 2004-12-06
- Published: 2005-07-21
- Granted: 2009-10-27
- Earliest claimed: 1997-07-25
- Assignees: Schering Corporation
- Inventors: J. Fernando Bazan
- Web page: https://patentgrep.com/patent/US7608690B2

## CPC

- C07K 14/54: Interleukins [IL]
- C07H 21/04: with deoxyribosyl as saccharide radical
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- Y10T 436/143333: Saccharide [e.g., DNA, etc.]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.

## Claims

### Claim 1

A recombinant antibody or antigen binding fragment thereof that binds to a polypeptide having the amino acid sequence of SEQ ID NO: 2.

### Claim 2 (depends on 1)

The antigen binding fragment of claim 1 selected from:
a) a Fab fragment;
b) a Fab2 fragment; or
c) a single chain antibody.

### Claim 3 (depends on 1)

The recombinant antibody or antigen binding fragment of claim 1, which binds said polypeptide with an affinity of at least 100 nM.

### Claim 4 (depends on 1)

The recombinant antibody or antigen binding fragment of claim 1, which binds said polypeptide with an affinity of at least 30 nM.

### Claim 5 (depends on 1)

The recombinant antibody or antigen binding fragment of claim 1, which binds said polypeptide with an affinity of at least 10 nM.

### Claim 6 (depends on 1)

The recombinant antibody or antigen binding fragment of claim 1, which binds said polypeptide with an affinity of at least 3 nM.

### Claim 7 (depends on 1)

The recombinant antibody or antigen binding fragment of claim 1, which binds said polypeptide with a dissociation constant (KD) of at least 3 μM.

### Claim 8 (depends on 1)

The recombinant antibody of claim 1, wherein said antibody is a full length antibody.

### Claim 9 (depends on 1)

The recombinant antibody of claim 1, wherein said antibody is a monoclonal antibody.

### Claim 10 (depends on 1)

The recombinant antibody of claim 1, wherein said antibody is an antagonist antibody.

### Claim 11 (depends on 1)

The recombinant antibody or antigen binding fragment of claim 1, comprising a detectable label.

### Claim 12 (depends on 11)

The recombinant antibody or antigen binding fragment of claim 11, wherein the detectable label is a radioactive or fluorescent label.

### Claim 13 (depends on 1)

A sterile composition comprising the recombinant antibody or antigen binding fragment of claim 1.

### Claim 14 (depends on 13)

The sterile composition of claim 13, wherein said sterile composition comprises an aqueous carrier.

### Claim 15 (depends on 14)

The sterile composition of claim 14, wherein said aqueous carrier comprises one or more of water, saline, or buffer.

### Claim 16 (depends on 1)

The recombinant antibody or antigen binding fragment of claim 1, which binds to a polypeptide having the amino acid sequence of residues 1-168 of SEQ ID NO: 2.

### Claim 17

A monoclonal antibody or antigen binding fragment thereof, that binds to a polypeptide having the amino acid sequence of SEQ ID NO:2.

### Claim 18 (depends on 17)

The antigen binding fragment of claim 17 selected from:
a) a Fab fragment;
b) a Fab2 fragment; or
c) a single chain antibody.

### Claim 19 (depends on 17)

The monoclonal antibody of claim 17, wherein said antibody is a full length antibody.

### Claim 20 (depends on 17)

The monoclonal antibody of claim 17, wherein said antibody is an antagonist antibody.

### Claim 21 (depends on 17)

The monoclonal antibody or antigen binding fragment of claim 17, comprising a detectable label.

### Claim 22 (depends on 21)

The monoclonal antibody or antigen binding fragment of claim 21, wherein the detectable label is a radioactive or fluorescent label.

### Claim 23 (depends on 17)

The monoclonal antibody or antigen binding fragment of claim 17, which binds said polypeptide with an affinity of at least 100 nM.

### Claim 24 (depends on 17)

The monoclonal antibody or antigen binding fragment of claim 17, which binds said polypeptide with an affinity of at least 30 nM.

### Claim 25 (depends on 17)

The monoclonal antibody or antigen binding fragment of claim 17, which binds said polypeptide with an affinity of at least 10 nM.

### Claim 26 (depends on 17)

The monoclonal antibody or antigen binding fragment of claim 17, which binds said polypeptide with an affinity of at least 3 nM.

### Claim 27 (depends on 17)

The monoclonal antibody or antigen binding fragment of claim 17, which binds said polypeptide with a dissociation constant (KD) of at least 3 μM.

### Claim 28 (depends on 17)

A sterile composition comprising the monoclonal antibody or antigen binding fragment of claim 17.

### Claim 29 (depends on 28)

The sterile composition of claim 28, wherein said sterile composition comprises an aqueous carrier.

### Claim 30 (depends on 29)

The sterile composition of claim 29, wherein said aqueous carrier comprises one or more of water, saline, or buffer.

### Claim 31 (depends on 17)

The monoclonal antibody or antigen binding fragment of claim 17, which binds to a polypeptide having the amino acid sequence of residues 1-168 of SEQ ID NO: 2.